NEW YORK, Aug. 13, 2024 /PRNewswire/ -- The world recently bid farewell to Dr. Stanley Taub, a true Renaissance man…
For the eighth consecutive year, the analytics underpinning the company's proprietary Health Insights Dashboard™ have been recognized for their quality and…
Regional Cancer Care Associates is pleased to announce the recognition of John Theurer Cancer Center as the #1 Cancer Program…
RADIAN's Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on…
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidineCompany anticipates new data…
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net…
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase…
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin…
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with…
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on…